Intelerad workflow solution to include Zebra Medical Vision’s AI offerings

Intelerad Medical Systems and Zebra Medical Vision have announced a new partnership involving Intelerad’s Odyssey workflow management solution.

As a part of this arrangement, Zebra-Med’s bundle of AI solutions, AI1, will now be included as a primary building block of Odyssey. The move, according to a prepared statement from both companies, is “designed to encourage the adoption of artificial intelligence without the prohibitive costs usually associated with such programs.”

Odyssey also charges users per study, a feature put in place to keep costs down for providers who may not want to pay a flat fee right off the bat. A 12-month trial is also being offered to celebrate the release of Odyssey, an offer only available “for a limited time.”

“Odyssey will deliver state-of-the-art clinical AI solutions directly integrated into the radiologists’ natural workflow and tailored to the needs of individual organizations,” Chris Wood, chief technology officer at Intelerad, said in the prepared statement. “With Zebra-Med’s AI1, we are committed to providing a broad and growing portfolio of high-value, innovative technology solutions to our customers and this unprecedented approach to artificial intelligence in radiology will extend our leadership position in workflow management.”

“We are excited to be supporting Intelerad’s team and the 300 healthcare organizations they serve, with our ‘all-in-one’ AI1 ever-growing portfolio of FDA-cleared AI products,“ Eyal Gura, CEO of Zebra Medical Vision, said in the same statement. “We are committed to bring more AI value in an integrated way to the workflow and in all modalities.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.